The FDA has given Medtronic approval to introduce its Attain Performa Model 4298 quadripolar lead and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) in the U.S.
Having four electrodes on a lead allows cardiologists to select from any one of 16 available pacing configurations. Additionally, the short distance between the inner two electrodes provides more ability to finely tune CRT-D therapy.
From the announcement:
The new quadripolar lead reduces the incidence of phrenic nerve stimulation (PNS), a potential side effect that results in muscle twitching, hiccups or shortness of breath. The Viva Quad XT device is equipped with the proprietary AdaptivCRT feature, which preserves normal heart rhythms and automatically adjusts to patients’ needs to customize therapy. The system includes VectorExpress(TM) technology, which reduces lead programming time to two minutes by providing physicians with clinically actionable information to help them select optimal pacing configurations for each patient.
The Attain Performa lead addresses the clinical challenges that can compromise lead position, offering implanting physicians more options to maintain lead position and optimize CRT therapy. The Model 4298 lead has a canted shape, and steroid on all four electrodes for lower pacing thresholds.